Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.

August 18, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with corresponding circulars and notifications issued thereunder, it is hereby informed to you that the Board of Directors of Alivus Life Sciences Limited at its meeting held on August 18, 2026, approved the share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited for an aggregate approx consideration INR 9.12 crores subject to adjustment as per Share purchase agreement. The relevant disclosure as prescribed under Regulation 30 of the SEBI LODR Regulations and SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure 1. You are requested to kindly takes note of the same. Thanking You, Your Sincerely, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl: As above Alivus Life Sciences Limited ( formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumba–i 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Annexure 1 S.No. Particulars Remarks 1. Name of the target entity, IQGEN-X Pharma Private Limited having its Registered details in brief such as size, Office at A-165, TTC Industrial Area, Khairane, Navi turnover etc. Mumbai 400705, Maharashtra, India Size- Authorised share capital Rs. 2,00,00,000/- divided into 20,00,000 equity shares of Rs.10/- each Turnover- INR 348 Lacs for financial year ended March 31, 2026. 2. Whether the acquisition would The acquisition does not fall within the related party fall within related party transaction. transaction(s) and whether the No promoter has any interest in the entity being promoter/ promoter group/ acquired. group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length” 3. Industry to which the entity Pharmaceuticals. being acquired belongs 4. Objects and impact of IQGEN-X Pharma Private Limited provides a wider acquisition (including but not spectrum for the Company to offer a complete end-to- limited to, disclosure of reasons end solution to its customers in both API and CDMO for acquisition of target entity, if space. its business is outside the main line of business of the listed entity) 5. Brief details of any No Government or regulatory approval required. governmental or regulatory approvals required for the acquisition 6. Indicative time period for December 6, 2026 or such date as may be agreed by the completion of the acquisition acquirer from the execution of the Share purchase Agreement (SPA), subject to fulfilment of Conditions Precedent in the SPA. The SPA provides that if the Condition Precedents are not met within the above said timelines from the execution, the sellers will enter into a Business Transfer Agreement with the Company whereby the entire business will be acquired by the Company from IQGEN-X Pharma Private Limited including the employees and assets. 7. Nature of consideration - Cash consideration whether cash consideration or share swap and details of the same 8. Cost of acquisition or the price The aggregate consideration is approx INR 9.12 crores at which the shares are acquired subject to customary adjustment as per SPA for acquisition of 8,60,589 equity shares of Rs.10/- each representing 76% of the paid up equity share capital of IQGEN-X Pharma Private Limited. Percentage of shareholding / 76% of the paid-up equity share capital consisting of 9. control acquired and / or 8,60,589 equity shares of the face value of Rs.10/- each number of shares acquired of IQGEN-X Pharma Private Limited. 10. Brief background about the IQGEN-X Pharma Private Limited is a company entity acquired in terms of incorporated under the Companies Act 2013 as a private products/line of business limited company in Oct 2016. acquired, date of incorporation, It is engaged in the business of formulation development history of last 3 years turnover, of Oral Solids, Sterile Injectables and Ophthalmic country in which the acquired solutions for regulated and semi regulated markets. entity has presence and any Turnover of last 3 years other significant information (in brief) 2025-26 INR 348.0 Lacs 2024-25 INR 318.2 Lacs 2023-24 INR 267.5 Lacs Country - India